

Biperiden

Section

Medicines for parkinsonism

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

Bromocriptine

Section

Antiseizure medicines

Oral > Solid: 2.5 mg; 5 mg

Indications

Parkinson disease

Cabergoline

Section

Antiseizure medicines

Oral > Solid: 0.5 mg

Indications

Parkinson disease

Carbamazepine

Section

Antiseizure medicines

Oral > Liquid: 100 mg per 5 mL

Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

Indications

Epilepsy or seizures

Cladribine

Section

Medicines for multiple sclerosis

Oral > Solid > tablet: 10 mg

Indications

Multiple sclerosis

Clonazepam

Section

Antiseizure medicines

Oral > Solid: 500 µg

Indications

Generalised myoclonic seizure

Diazepam

Section

Antiseizure medicines

Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system

Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Indications

Therapeutic equivalent to lorazepam for

Status epilepticus

Status epilepticus

Dihydroergocryptine mesylate

Section

Antiseizure medicines

Oral > Solid:

Indications

Parkinson disease

Donepezil

Section

Medicines for diseases of the nervous system

Oral > Liquid: 1 mg per mL (hydrochloride)

Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)

Indications

Dementia due to Alzheimer disease

Ethosuximide

Section

Antiseizure medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid: 250 mg

Indications

Absence seizures, typical

Glatiramer acetate

Section

Medicines for multiple sclerosis

Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Lamotrigine

Section

Antiseizure medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

Indications

Epilepsy or seizures

Levetiracetam

Section

Antiseizure medicines

Oral > Liquid: 100 mg per mL

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg

Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

Indications

Epilepsy or seizures

Status epilepticus

Levodopa

Section

Antiseizure medicines

Oral > Solid: 250 mg

Indications

Parkinson disease

Levodopa + benserazide

Section

Medicines for parkinsonism

Indications

Therapeutic equivalent to levodopa + carbidopa for

Parkinson disease

Levodopa + carbidopa

Section

Medicines for parkinsonism

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

Lorazepam

Section

Antiseizure medicines

Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

Indications

Status epilepticus

Magnesium sulfate

Section

Antiseizure medicines

Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)

Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

Indications

Severe pre-eclampsia

Eclampsia

Midazolam

Section

Antiseizure medicines

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Indications

Therapeutic equivalent to lorazepam for

Status epilepticus

Status epilepticus

Ocrelizumab

Section

Medicines for multiple sclerosis

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

Relapsing-remitting multiple sclerosis

Multiple sclerosis

Phenobarbital

Section	Indications
Antiseizure medicines Oral > Liquid: 15 mg per 5 mL Oral > Solid: 15 to 100 mg Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)	Epilepsy or seizures Status epilepticus

Phenytoin

Section	Indications
Antiseizure medicines Oral > Liquid: 30 mg per 5 mL (phenytoin) Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium) Oral > Solid > tablet: 50 mg (phenytoin) (chewable) Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)	Epilepsy or seizures

Pramipexole

Section	Indications
Antiseizure medicines Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release	Parkinson disease

Risdiplam

Section	Indications
Medicines for diseases of the nervous system Oral > Liquid: 0.75 mg per mL powder for oral liquid	Spinal muscular atrophy

Rituximab

Section	Indications
Medicines for multiple sclerosis Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial	Multiple sclerosis

Ropinirole

Section

Antiseizure medicines

Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 mg immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

Parkinson disease

Trihexyphenidyl

Section

Antiseizure medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

Indications

Parkinson disease

Therapeutic equivalent to [biperiden](#) for

Parkinson disease

Valproic acid (sodium valproate)

Section

Antiseizure medicines

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule

Indications

Epilepsy or seizures

Status epilepticus